

September 05, 2019

To The Corporate Relations Department BSE Limited Phiroz Jeejeebhoy Towers, 25 th Floor, Dalal Street Mumbai – 400001 Code: 540222	To The Listing Department National Stock Exchange of India Limited Exchange Plaza, Bandra Kurla Complex, Bandra (East) Mumbai – 400 051 Code: LAURUSLABS
--	---

Dear Sirs,

Sub: Laurus Labs receives an EIR from USFDA for its API Units 1 & 3 and also received an ERP approval for fixed dose combination TLE400 from Global Fund


The Company is pleased to announce that it has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (US FDA) for its API Units 1& 3, located at Parawada, Visakhapatnam, for the inspection conducted in June 2019.

And in FDF segment Laurus Labs received Global Fund (GF) ERP (Expert Review Panel) approval for FDC (Fixed Dose Combination) TLE 400 (Tenofovir/Lamivudine/Efavirenz 300/300/400mg) for supply in GF funded projects. Laurus Labs is one among the three companies to receive the approval for this product in ART (Anti Retro Viral Therapy).

A press release to this extent is attached for your information and records.

Thanking you,

Yours sincerely,
For Laurus Labs Limited


G. Venkateswar Reddy
Company Secretary



Encl: a.a.

Laurus Labs receives an EIR from USFDA for its API Units 1 & 3 and also received an ERP approval for fixed dose combination TLE₄₀₀ from Global Fund

Hyderabad, September 05, 2019, Laurus Labs Ltd. (BSE: 540222, NSE: LAURUSLABS, ISIN: INE947Q01010)

Laurus Labs Limited, a leading research and development driven pharmaceutical company has received the Establishment Inspection Report (EIR) from US Food and Drug Administration (US FDA) for its API Units 1& 3, located at Parawada, Visakhapatnam, for the inspection conducted in June 2019.

And in FDF segment Laurus Labs received Global Fund (GF) ERP (Expert Review Panel) approval for FDC (Fixed Dose Combination) TLE 400 (Tenofovir/Lamivudine/Efavirenz 300/300/400mg) for supply in GF funded projects. Laurus Labs is one among the three companies to receive the approval for this product in ART (Anti Retro Viral Therapy).

This approval enables Laurus Labs to participate directly in GF and also In-Country tenders based on GF funding across Sub-Saharan African region along with our other ARV portfolio comprising of TLD (Tenofovir/Lamivudine/Dolutegravir 300/300/50mg), DTG (Dolutegravir 50mg) and ET (Emtricitabine/Tenofovir 200/300mg).

TLE 400 is the alternative first line regimen for treatment of HIV/AIDS as per the WHO guidelines issued in July 2019.

About Laurus Labs Limited:


Laurus Labs is a leading research & development driven and fully integrated pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus also manufactures APIs in Oncology and other therapeutic areas. Its strategic and early investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area. The company has also ventured into develop a Finished Dosages Forms on the back of existing strengths in APIs with a current capacity of 5 billion units per year, expandable up to 8 billion units per year. The Company is also driving growth opportunities in the Synthesis and Ingredients businesses. **Corporate Identification No: L24239AP2005PLC047518.**

For more information about us, please visit <http://www.lauruslabs.com> or Contact particulars:

Pavan Kumar N
Laurus Labs Ltd.

Tel: +91 40 3980 4380

Email: mediarelations@lauruslabs.com



DISCLAIMER: Certain statements in this document may be forward-looking statements. Such forward-looking statements are subject to certain risks and uncertainties like regulatory changes, local political or economic developments and many other factors that could cause our actual results to differ materially from those contemplated by the relevant forward-looking statements. Laurus Labs Limited (Laurus) will not be in any way responsible for any action taken based on such statements and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.